Miragen Therapeutics Inc., of Boulder, Colo., reported new data demonstrating that systemic administration of its second-generation microRNA-29 mimic, a micro-RNA targeted therapeutic candidate for idiopathic pulmonary fibrosis, efficiently reduced extracellular matrix deposition in a series of preclinical studies. The data were presented at the American Thoracic Society conference in Dallas.